HCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.
Bhattacharya et al., 6/9/2020, retrospective, India, South Asia, preprint, 7 authors.
risk of COVID-19 case, 80.7% lower, RR 0.19, p = 0.001, treatment 4 of 54 (7.4%), control 20 of 52 (38.5%).
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of
many trials.